On February 24, 2026, Novo Nordisk announced it will significantly reduce the wholesale acquisition cost (WAC) of several of its GLP‑1 therapies, effective January 1, 2027.
New WAC: $675 per month.
This new pricing will apply to:
• Wegovy® (semaglutide) 2.4mg injection and 25mg tablet
• Ozempic® (semaglutide) 0.5mg, 1mg, and 2mg injections
• Rybelsus® (semaglutide) 7mg and 14mg tablets
Here’s the price impact employers should be watching:
• Wegovy®: ~50% WAC reduction
• Ozempic® & Rybelsus®: ~35% WAC reduction
For plan sponsors, these cuts could meaningfully shift GLP‑1 strategy and spend.
These therapies play a critical role in:
• Chronic weight management and reduction of major adverse cardiovascular events (Wegovy)
• Glycemic control and cardiovascular risk reduction in type 2 diabetes (Ozempic, Rybelsus)
Notably: Novo Nordisk indicated that direct‑to‑consumer and self‑pay pricing will not change. It remains unclear whether unlisted strengths will see similar reductions.
